Serum‐derived microribonucleic acids as potential novel biomarkers for slowly progressive type 1 diabetes mellitus
Journal of Diabetes Investigation · 2026-11 · 17 (11) · 1876-1887
DOI: 10.1111/jdi.70402 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Diabetes Investigation, online erschienen am 04.08.2026. Verfasst von Hideyuki Okuma und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diabetes and Endocrinology, Graduate School of Interdisciplinary Research, Faculty of Medicine, University of Yamanashi, Yamanashi, Jap…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Biomarkers, MicroRNAs. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Society for the Promotion of Science (JSPS), The Japan Diabetes Society.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Objectives
We aimed to identify microribonucleic acids (miRNAs) that could serve as biomarkers for slowly progressive type 1 diabetes mellitus (SPIDDM). Materials and Methods We conducted a retrospective study of adult patients with SPIDDM who fulfilled the criteria for SPIDDM (definite) ( n = 60), type 2 diabetes mellitus (T2DM) ( n = 59), and healthy controls ( n = 50) to analyze the serum expression levels of 40 miRNAs reported to be altered in latent autoimmune diabetes in adults and type 1 diabetes using quantitative real‐time polymerase chain reaction, specifically analyzing serum collected at the time of diagnosis as SPIDDM (probable) in the SPIDDM group. For miRNAs showing significant differences between the groups, we performed logistic regression analysis. In the SPIDDM group, we performed linear regression analysis on miRNAs correlated with the C‐peptide index (CPI) at the last outpatient visit as identified by Spearman's rank correlation.
Results
The serum expression levels of miR‐143‐3p, miR‐21‐5p, miR‐223‐3p, and miR‐517b‐3p differed significantly in the SPIDDM group compared with the type 2 diabetes mellitus and control groups. Multivariate logistic regression analysis distinguishing SPIDDM from type 2 diabetes mellitus revealed miR‐21‐5p, miR‐223‐3p, and miR‐517b‐3p as independent discriminators. Correlation and multivariate linear regression analyses revealed that miR‐150‐5p was selected as an independent predictor of CPI at the last outpatient visit.
Conclusion
This study identified serum miRNAs as potential biomarkers in adult patients with SPIDDM, particularly miR‐150‐5p as a candidate marker for predicting subsequent decline in insulin secretion.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Diabetes and Endocrinology, Graduate School of Interdisciplinary Research, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan.
- Department of Diabetes and Endocrinology, Nerima Hikarigaoka Hospital, Tokyo, Japan.
- Department of Endocrinology and Metabolism, Toranomon Hospital, Tokyo, Japan.
ORCID-Profile: Hideyuki Okuma, Takahiro Tsutsumi, Kyoichiro Tsuchiya
Förderung
- Japan Society for the Promotion of Science (JSPS)
- The Japan Diabetes Society
Zitieren
APA
Okuma, H., Tsutsumi, T., Ichijo, M., Kobayashi, T., & Tsuchiya, K. (2026). Serum‐derived microribonucleic acids as potential novel biomarkers for slowly progressive type 1 diabetes mellitus. Journal of Diabetes Investigation, 17(11), 1876-1887. https://doi.org/10.1111/jdi.70402
Vancouver
Okuma H, Tsutsumi T, Ichijo M, Kobayashi T, Tsuchiya K. Serum‐derived microribonucleic acids as potential novel biomarkers for slowly progressive type 1 diabetes mellitus. Journal of Diabetes Investigation. 2026;17(11):1876-1887. doi:10.1111/jdi.70402
BibTeX
@article{Okuma2026,
author = {Okuma, Hideyuki and Tsutsumi, Takahiro and Ichijo, Masashi and Kobayashi, Tetsuro and Tsuchiya, Kyoichiro},
title = {Serum‐derived microribonucleic acids as potential novel biomarkers for slowly progressive type 1 diabetes mellitus},
journal = {Journal of Diabetes Investigation},
year = {2026},
volume = {17},
number = {11},
pages = {1876--1887},
doi = {10.1111/jdi.70402}
}
EUVIMED